Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

Stopped Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.

Conditions

• Lung Cancer
• Esophageal Cancer
• Malignant Pleural Mesothelioma
• Sarcoma
• Thymic Carcinoma

Interventions

• BIOLOGICAL: Allogeneic Tumor Cell Vaccine (K562)
• DRUG: Celecoxib
• DRUG: cyclophosphamide

Sponsor

National Cancer Institute (NCI)